<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941525</url>
  </required_header>
  <id_info>
    <org_study_id>83155</org_study_id>
    <secondary_id>EudraCT: 2008-004629-41</secondary_id>
    <nct_id>NCT00941525</nct_id>
  </id_info>
  <brief_title>Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure</brief_title>
  <acronym>CCT-IOP</acronym>
  <official_title>Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 24-hour fluctuation of intraocular pressure
      (IOP) is associated with central corneal thickness (CCT) in subjects with ocular hypertension
      or open angle glaucoma and in age-matched controls. Also to evaluate whether mean IOP
      reduction as a response to latanoprost (0.005% Xalatan) is associated with CCT, after a
      4-weeks period of treatment.

      Also, to evaluate whether 24-hour fluctuation of IOP is associated with corneal hysteresis
      (CH) measured by Ocular Response Analyzer (ORA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation analyses between mean central corneal thickness (CCT) and 24-hour intraocular pressure (IOP) fluctuation and between mean CCT and mean IOP reduction from baseline after a 4-weeks period of treatment with latanoprost.</measure>
    <time_frame>Before and after a 4-weeks period of treatment with latanoprost.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation analyses between corneal hysteresis (CH) and 24-hour intraocular pressure (IOP) fluctuation and between CH and mean IOP reduction from baseline after a 4-weeks period of treatment with latanoprost.</measure>
    <time_frame>Before and after a 4-weeks period of treatment with latanoprost.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Ocular hypertensives</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study includes two groups.
Subjects with ocular hypertension and
Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period</description>
    <arm_group_label>Ocular hypertensives</arm_group_label>
    <other_name>0.005% Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males and females &gt;50 years old with:

          -  Primary Open-Angle Glaucoma newly diagnosed or with anti-glaucoma medical treatment &lt;
             =12 weeks

          -  Pseudoexfoliative Glaucoma newly diagnosed or with anti-glaucoma medical treatment &lt;=
             12 weeks

          -  Ocular Hypertensives newly diagnosed or with anti-glaucoma medical treatment &lt;= 12
             weeks

          -  Age-matched controls

          -  IOP&gt;=22mmHg at the eligibility visit for glaucoma patients and ocular hypertensives

        Exclusion Criteria:

        For Eye

          -  Use of any ophthalmic medication (drops) during the study (except for natural tears)

          -  Inflammation of any aetiology

          -  Previous eye surgery or laser

          -  Corneal abnormalities (oedema, dystrophies etc) For Subjects

          -  Systemic diseases which affect the cornea (such as autoimmune diseases)

          -  Inability to participate due to advanced age or serious illness

          -  Mean IOP&gt;36mmHg in either eye at the eligibility visit.

          -  Subjects who cannot safety discontinue use of all IOP-lowering medication(s) for
             washout

          -  Subjects with severe central visual field loss in either eye. Severe central visual
             field loss is defined as sensitivity &lt;=10dB in at least 2 of the 4 visual field test
             points closest to the point of fixation

          -  Other types of glaucoma (such as angle-closure glaucoma and secondary glaucomas)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fotis Topouzis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A' Department of Ophthalmology, Aristotle University of Thessaloniki, AHEPA Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J; Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004 Sep;111(9):1627-35.</citation>
    <PMID>15350314</PMID>
  </reference>
  <reference>
    <citation>Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000 Apr;9(2):134-42.</citation>
    <PMID>10782622</PMID>
  </reference>
  <reference>
    <citation>European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007 Jan;114(1):3-9. Epub 2006 Oct 27.</citation>
    <PMID>17070596</PMID>
  </reference>
  <reference>
    <citation>Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30.</citation>
    <PMID>12049575</PMID>
  </reference>
  <reference>
    <citation>Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2566-73.</citation>
    <PMID>10937568</PMID>
  </reference>
  <reference>
    <citation>Larsson LI, Mishima HK, Takamatsu M, Orzalesi N, Rossetti L. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S90-6. Review.</citation>
    <PMID>12204704</PMID>
  </reference>
  <reference>
    <citation>Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003 Apr;121(4):453-7.</citation>
    <PMID>12695241</PMID>
  </reference>
  <reference>
    <citation>Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004 Sep;138(3):389-95.</citation>
    <PMID>15364220</PMID>
  </reference>
  <reference>
    <citation>Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006 Feb;113(2):239-46.</citation>
    <PMID>16458092</PMID>
  </reference>
  <reference>
    <citation>Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg. 2005 Jan;31(1):156-62.</citation>
    <PMID>15721708</PMID>
  </reference>
  <reference>
    <citation>Congdon NG, Broman AT, Bandeen-Roche K, Grover D, Quigley HA. Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol. 2006 May;141(5):868-75. Epub 2006 Mar 9.</citation>
    <PMID>16527231</PMID>
  </reference>
  <reference>
    <citation>Kotecha A, Elsheikh A, Roberts CR, Zhu H, Garway-Heath DF. Corneal thickness- and age-related biomechanical properties of the cornea measured with the ocular response analyzer. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5337-47.</citation>
    <PMID>17122122</PMID>
  </reference>
  <reference>
    <citation>Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001 Aug;108(8):1439-44.</citation>
    <PMID>11470697</PMID>
  </reference>
  <reference>
    <citation>Kida T, Liu JH, Weinreb RN. Effect of 24-hour corneal biomechanical changes on intraocular pressure measurement. Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4422-6.</citation>
    <PMID>17003435</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Fotis Topouzis</investigator_full_name>
    <investigator_title>Professior</investigator_title>
  </responsible_party>
  <keyword>Central corneal thickness</keyword>
  <keyword>24hour fluctuation of intraocular pressure</keyword>
  <keyword>Open angle glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

